AR104241A1 - Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos - Google Patents

Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos

Info

Publication number
AR104241A1
AR104241A1 ARP160100992A ARP160100992A AR104241A1 AR 104241 A1 AR104241 A1 AR 104241A1 AR P160100992 A ARP160100992 A AR P160100992A AR P160100992 A ARP160100992 A AR P160100992A AR 104241 A1 AR104241 A1 AR 104241A1
Authority
AR
Argentina
Prior art keywords
tetrahydrofide
thiazine
derivatives
bace1 inhibitors
selective bace1
Prior art date
Application number
ARP160100992A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR104241A1 publication Critical patent/AR104241A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/28Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C07C309/31Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups by alkyl groups containing at least three carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

Reivindicación 1: Un compuesto de la fórmula (1), o una sal de este aceptable desde el punto de vista farmacéutico.
ARP160100992A 2015-04-29 2016-04-13 Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos AR104241A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562154242P 2015-04-29 2015-04-29

Publications (1)

Publication Number Publication Date
AR104241A1 true AR104241A1 (es) 2017-07-05

Family

ID=55861291

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160100992A AR104241A1 (es) 2015-04-29 2016-04-13 Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos

Country Status (40)

Country Link
US (1) US10011610B2 (es)
EP (1) EP3288949B1 (es)
JP (2) JP2017515831A (es)
KR (1) KR101979534B1 (es)
CN (1) CN107531728B (es)
AR (1) AR104241A1 (es)
AU (1) AU2016254980B2 (es)
BR (1) BR112017020180A2 (es)
CA (1) CA2981091A1 (es)
CL (1) CL2017002651A1 (es)
CO (1) CO2017010725A2 (es)
CR (1) CR20170433A (es)
CY (1) CY1122375T1 (es)
DK (1) DK3288949T3 (es)
DO (1) DOP2017000240A (es)
EA (1) EA032293B1 (es)
EC (1) ECSP17071769A (es)
ES (1) ES2765646T3 (es)
GT (1) GT201700227A (es)
HK (1) HK1243709A1 (es)
HR (1) HRP20192237T1 (es)
HU (1) HUE047160T2 (es)
IL (1) IL254252A0 (es)
MA (1) MA41975B1 (es)
MD (1) MD3288949T2 (es)
ME (1) ME03660B (es)
MX (1) MX2017013694A (es)
MY (1) MY180727A (es)
NZ (1) NZ735249A (es)
PE (1) PE20180048A1 (es)
PH (1) PH12017501955A1 (es)
PL (1) PL3288949T3 (es)
PT (1) PT3288949T (es)
RS (1) RS59729B1 (es)
SG (1) SG11201708003WA (es)
SI (1) SI3288949T1 (es)
SV (1) SV2017005547A (es)
TN (1) TN2017000448A1 (es)
TW (1) TWI619719B (es)
WO (1) WO2016176118A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR103680A1 (es) * 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
AR110470A1 (es) * 2016-10-21 2019-04-03 Lilly Co Eli Terapia de combinación para tratar la enfermedad de alzheimer
US11559528B2 (en) * 2019-09-05 2023-01-24 The Cleveland Clinic Foundation BACE1 inhibition for the treatment of cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1896478B1 (en) 2005-06-14 2014-05-21 Merck Sharp & Dohme Corp. Aspartyl protease inhibitors
US8158620B2 (en) * 2008-01-18 2012-04-17 Eisai R&D Management Co., Ltd. Fused aminodihydrothiazine derivatives
NZ589590A (en) 2008-06-13 2012-05-25 Shionogi & Co Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity
ES2539859T3 (es) 2008-09-30 2015-07-06 Eisai R&D Management Co., Ltd. Nuevo derivado de aminodihidrotiazina condensado
AR077277A1 (es) 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
WO2011071057A1 (ja) 2009-12-09 2011-06-16 塩野義製薬株式会社 含硫黄複素環誘導体を含有するアルツハイマー症の治療用または予防用医薬組成物
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) * 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101139D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
WO2012147762A1 (ja) * 2011-04-26 2012-11-01 塩野義製薬株式会社 ピリジン誘導体およびそれを含有するbace1阻害剤
AR086539A1 (es) 2011-05-24 2014-01-08 Bristol Myers Squibb Co COMPUESTOS PARA LA REDUCCION DE LA PRODUCCION DE b-AMILOIDE
WO2014015125A1 (en) 2012-07-19 2014-01-23 Eisai R&D Management Co., Ltd. Fused aminodihydrothiazine derivative salts and uses thereof
JP2014101354A (ja) * 2012-10-24 2014-06-05 Shionogi & Co Ltd Bace1阻害作用を有するオキサジン誘導体
TWI593692B (zh) 2013-03-12 2017-08-01 美國禮來大藥廠 四氫吡咯并噻嗪化合物
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
TWI675034B (zh) 2016-05-20 2019-10-21 美商美國禮來大藥廠 四氫呋喃并<img align="absmiddle" height="18px" width="27px" file="d10999.TIF" alt="其他非圖式 ed10999.png" img-content="tif" orientation="portrait" inline="yes" giffile="ed10999.png"></img>化合物及其作為選擇性BACE1抑制劑之用途
JP2019524788A (ja) 2016-08-11 2019-09-05 イーライ リリー アンド カンパニー アミノチアジンおよびbace1阻害剤としてのそれらの使用

Also Published As

Publication number Publication date
PE20180048A1 (es) 2018-01-15
EP3288949A1 (en) 2018-03-07
CR20170433A (es) 2017-11-07
CA2981091A1 (en) 2016-11-03
EP3288949B1 (en) 2019-11-06
CN107531728A (zh) 2018-01-02
TN2017000448A1 (en) 2019-04-12
AU2016254980B2 (en) 2018-06-21
MA41975B1 (fr) 2020-01-31
CN107531728B (zh) 2019-11-19
NZ735249A (en) 2018-08-31
TW201710268A (zh) 2017-03-16
CO2017010725A2 (es) 2018-01-31
MY180727A (en) 2020-12-08
JP6777668B2 (ja) 2020-10-28
SV2017005547A (es) 2018-04-24
SI3288949T1 (sl) 2019-12-31
PT3288949T (pt) 2020-01-16
PL3288949T3 (pl) 2020-06-01
GT201700227A (es) 2018-11-23
HRP20192237T1 (hr) 2020-03-06
EA201792109A1 (ru) 2018-03-30
JP2017515831A (ja) 2017-06-15
MX2017013694A (es) 2018-03-02
JP2018140987A (ja) 2018-09-13
ME03660B (me) 2020-07-20
US10011610B2 (en) 2018-07-03
PH12017501955A1 (en) 2018-03-19
ES2765646T3 (es) 2020-06-10
CL2017002651A1 (es) 2018-04-20
SG11201708003WA (en) 2017-10-30
HUE047160T2 (hu) 2020-04-28
CY1122375T1 (el) 2021-01-27
EA032293B1 (ru) 2019-05-31
TWI619719B (zh) 2018-04-01
RS59729B1 (sr) 2020-02-28
MD3288949T2 (ro) 2020-03-31
WO2016176118A1 (en) 2016-11-03
IL254252A0 (en) 2017-10-31
KR101979534B1 (ko) 2019-05-16
BR112017020180A2 (pt) 2018-06-12
DK3288949T3 (da) 2020-01-13
AU2016254980A1 (en) 2017-09-21
HK1243709A1 (zh) 2018-07-20
DOP2017000240A (es) 2017-11-15
ECSP17071769A (es) 2018-02-28
KR20170131597A (ko) 2017-11-29
US20160318953A1 (en) 2016-11-03

Similar Documents

Publication Publication Date Title
EA201892128A1 (ru) Гетероциклические амиды, полезные в качестве модуляторов
PH12017501523A1 (en) Selective bace1 inhibitors
MA39749A (fr) Dérivés de pipéridine-dione
WO2016011390A8 (en) Irak4 inhibiting agents
SV2016005351A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
DOP2015000201A (es) Compuestos de azabencimidazol como inhibidores de pde4 isoenzimas para el tratamiento del snc y otros trastornos
AR098274A1 (es) Inhibidor de grelina o-acil transferasa
PH12016501517B1 (en) Tetrazolone-substituted dihydropyridinone mgat2 inhibitors
EA201790627A1 (ru) СТИМУЛЯТОРЫ рГЦ
MX2018004979A (es) Compuesto piranodipiridinico.
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
NZ725165A (en) Analogues of 4h-pyrazolo[1,5-α]benzimidazole compound as parp inhibitors
CO2019005165A2 (es) Compuesto de piridona como inhibidor de c-met
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
AR104241A1 (es) Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
AR110770A1 (es) Moduladores del canal de potasio
MY176508A (en) Anti-enterovirus 71 thiadiazolidine derivative
AR107163A1 (es) Inhibidores de quinasa
AR102810A1 (es) Derivado de macrólido sustituido en la posición c-4
AR115865A2 (es) Compuestos terapéuticos
AR110744A1 (es) Inhibidores bicíclicos de histona desacetilasa
AR108363A1 (es) Compuestos de tetrahidrofurooxazina y su uso como inhibidores de bace1 selectivos
TH168624B (th) อนุพันธ์กลูโคไพแรโนซิล-ซับสทิทิวเทด อินโดล-ยูเรีย และการใช้สารเหล่านั้น เป็นตัวยับยั้ง sglt

Legal Events

Date Code Title Description
FB Suspension of granting procedure